

FOLEYRECEIVED
CENTRAL FAX CENTER

SEP 15 2005

FOLEY & LARDNER LLP
ATTORNEYS AT LAWWASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143
TELEPHONE: 202.672.5300
FACSIMILE: 202.672.5399
WWW.FOLEY.COM

FACSIMILE TRANSMISSION

Total # of Pages 3 (including this page)

TO:	PHONE #:	FAX #:
Susan Ungar U.S. Patent and Trademark Office		571.273.0837

From : Beth A. Burrous
Sender's Direct Dial : 202.672.5475
Date : September 12, 2005
Client/Matter No : 034536-0405
User ID No : 0104

MESSAGE:

If there are any problems with this transmission or if you have not
received all of the pages, please call .

Operator:	Time Sent:	Return Original To: Jean J. Dar
-----------	------------	------------------------------------

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

XXXXXXX.XA

Cover Page 1 of 1

FOLEY & LARDNER LLP

PAGE 1/3 * RCVD AT 9/12/2005 11:18:35 AM [Eastern Daylight Time] * SVR:USPTO-EFAXF-6/26 * DNIS:2730837 * CSID:5145 * DURATION (mm-ss):01-00

SEP 15 2005



FOLEY & LARDNER LLP
ATTORNEYS AT LAW
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143
TELEPHONE: 202.672.5300
FACSIMILE: 202.672.5399
WWW.FOLEY.COM

MEMORANDUM

CLIENT-MATTER NUMBER
034536-0405

TO: Examiner Susan Ungar,
U.S. Patent and Trademark Office
Art Unit 1642

FROM: Todd Spalding

CC: Beth Burrous

DATE: September 9, 2005

RE: U.S. Patent Application No. 10/073,064

Further to our telephone conversation on September 7, 2005, Applicants consent to amending the description of Figures 2A, 2B and 2C in the captioned patent application.

In that regard, please substitute the following three paragraphs for the first two full paragraphs on page 25 of the specification:

FIG. 2 shows ~~the~~ provides an overview of various forms of MDK1 RTKs.

FIG. 2A shows the nucleotide sequence of MDK1-T1 (as set forth in SEQ ID NO:4) beginning with nucleotide 1913 and FIG. 2B shows the nucleotide sequence of MDK1-T2 (as set forth in SEQ ID NO:6). ~~Sequences are shown~~ beginning with nucleotide 1913. The divergent sequence due to alternative splicing is shown underlined, as is the polyadenylation motif (AATAAA) (SEQ.

FOLEY

I.D. NO. 8) in the sequence of MDK1-T1. ~~The missing nucleotide stretches are indicated (---).~~

~~FIG. 2B~~ FIG. 2C shows a schematic representation of MDK1 and its variants. The open reading frame is indicated by boxes, the untranslated regions of the MDK1 sequences are given in bold lines. Below, the amino acid sequence variations in the marked region of the different forms of MDK1 are shown. The missing nucleotide stretches are indicated (- - -). The sequences shown each begin at amino acid residue number 535 in MDK1 (SEQ ID NO:2), MDK1-T1 (SEQ ID NO:3), MDK1-T2 (SEQ ID NO:5), MDK1-A1 (SEQ ID NO:11) and MDK1-A2 (SEQ ID NO:12).

BEST AVAILABLE COPY